22 Jul Cook MyoSite
Ryan Pruchnic, Managing Vice President
Oct. 13 | 9:15am | BlueRock Therapeutics Ballroom
In 2002, Cook MyoSite was formed to guide the Cook Group organization into the expanding world of cellular technologies through the development and subsequent commercialization of technology related to the collection, selection, and expansion of human skeletal muscle cells for the treatment of various disorders. Cook MyoSite’s lead technology, autologous muscle derived cells (AMDC), is a personalized regenerative cell therapy created from muscle progenitor cells that are isolated from human adult muscle and are theorized to engraft into existing dysfunctional or weakened target tissue to improve muscle function. The AMDC technology is being clinically investigated for female stress urinary incontinence, fecal incontinence, underactive bladder, and tongue dysphagia. To date, more than 600 subjects have participated in the AMDC clinical program.